1. Introduction {#s0005}
===============

Although several chemotherapeutic agents are currently being used to treat human cancers, either alone or in combination, they have limited effectiveness and the response rates remain largely unimproved in clinical trials ([@b0095], [@b0110]). Despite major advances in chemotherapeutic management and cancer biology, cancer still poses a serious threat to human health globally ([@b0040], [@b0055]). Moreover, the great similarity between tumor and normal cells and diversity of tumor types are the main hurdles preventing the development of an ultimate anticancer therapy ([@b0105]). Thus, persistent commitment to the arduous task of discovering and designing new anticancer agents remains critically essential.

The epidermal growth factor receptor (EGFR) plays a vital role in cell growth regulation and is considered one of the most intensely studied targets of tyrosine kinase (TK) inhibitors ([@b0100], [@b0145]). Several TKs play important roles in cell proliferation, differentiation, metastasis and survival, and their unregulated activation through mechanisms such as point mutations can lead to a large percentage of clinical cancers ([@b0100], [@b0145], [@b0060]). EGFR is overexpressed in numerous tumors, including brain, lung, bladder, ovarian, colon, breast, head, and prostate tumors ([@b0115], [@b0125], [@b0145], [@b0060]). Moreover, EGFR hyperactivation or aberrations in TKs have been implicated in other diseases including polycystic kidney disease, psoriasis, asthma, and diabetes.

Members of the erbB family of EGFR-TKs, which include erbB2 (HER2), erbB3 (HER3), and erbB4 (HER4), are overexpressed in a significant proportion of human tumors, and this overexpression is associated with poor prognosis of the disease ([@b0140], [@b0065], [@b0095]). Thus, inhibitors of erbB1 and erbB2 have been identified as potential anticancer drugs ([@b0130], [@b0095]).

Of several candidate compounds that have been synthesized and tested, gefitinib ([Fig.1](#f0005){ref-type="fig"}a) is the most potent and selective EGFR-TK inhibitor reported to date that, along with erlotinib ([Fig.1](#f0005){ref-type="fig"}b), has been approved by the United States Food and Drug Administration (US FDA) for the treatment of non-small cell lung cancer (NSCLC) ([@b0070], [@b0080], [@b0085]). Gefitinib, which belongs to a new class of quinazolines, inhibits EGFR-TK overexpression through its effect on EGFR autophosphorylation and EGF-stimulated signal transduction. Hence, designing compounds with EGFR-TK inhibitory activity is an attractive chemotherapeutic strategy against malignant and nonmalignant epithelial diseases. Recently somatic mutations in the TK domain of erbB1 have been observed in a subgroup of gefitinib- and erlotinib-treated NSCLC patients ([@b0135], [@b0120]). The focus is now on developing molecules with multiple kinase inhibition, particularly erbB1 and erbB2 inhibition ([@b0075]).Fig. 1Chemical structure of gefitinib, erlotinib, and quinazolines.

Owing to the current interest on quinazolines ([Fig.1](#f0005){ref-type="fig"}c) as antitumor agents ([@b0020], [@b0005], [@b0010], [@b0110]) and our ongoing studies on the quinazoline scaffold that are aimed at finding new leads with potential cytotoxic effects, we synthesized several new quinazoline derivatives (**3**--**16**, **24,** and **26**) containing a butyl group with different fragments and evaluated their *in vitro* cytotoxicity against HeLa and MDA-MB231 cancer cells. Additionally, we synthesized some derivatives (**17**--**23** and **25**) containing a benzyl group from the previously prepared parent compounds (**1**and **2**). In the present study, various functional groups were specifically incorporated at positions 3, 6, and 8 of the quinazoline scaffold to investigate the effect of various electronic environments on the cytotoxicity of the target molecules.

2. Materials and methods {#s0010}
========================

2.1. Chemistry {#s0015}
--------------

The NMR spectra were measured on a Bruker AMX 500 spectrometer (Bruker, Billerica, MA, USA) in deuterated dimethyl sulfoxide (DMSO-*d*~6~) and reported as *δ* (ppm) values relative to tetramethylsilane (TMS) at 500 and 125 MHz for ^1^H and ^13^C NMR, respectively. *J* values were recorded in Hz. The electrospray ionization mass spectrometry (ESI-MS) spectra were recorded using a Micromass Quattro micro™ triple-quadruple tandem mass spectrometer (Waters Corp., Milford, MA, USA). The X-ray data were collected on a Bruker APEX-II D8 Venture area diffractometer using graphite monochromatic Mo Kα radiation (λ = 0.71073 Å) at 100(2) K. The uncorrected melting point (mp) values were determined using a Stuart SMP10 melting point apparatus with open glass capillaries. The reactions were followed, and the product purity was checked by thin layer chromatography (TLC) on a DC-Mikrokarten Polygram® SIL G/UV~254,~ TLC plate (Thickness: 0.25 mm; Macherey-Nagel, Düren, Germany).

2.2. Preparation of 3-butyl-2,3-dihydro-6-methyl-2-thioxoquinazolin-4(1*H*)-one (**3**) {#s0020}
---------------------------------------------------------------------------------------

A mixture of butyl isothiocyanate (5 mmol) and 2-amino-5-methylbenzoic acid (5 mmol) in ethanol (15 mL) or *N,N*-dimethylformamide (DMF) (10 mL) was refluxed in the presence of triethylamine (Et~3~N, 2.4 mmol) for 2 h. The mixture was then cooled and poured into ice/water ([@b0055]). The resulting solid was filtered, washed with water, and dried. Yield: 90%; mp: 230--231 °C; ^1^H NMR (DMSO-*d*~6~) *δ* (ppm): 12.85 (s, 1H, ---NH---), 7.75 (br s, 1H, H-5), 7.56 (br d, *J* = 8 Hz, 1H, H-7), 7.29 (d, *J* = 8.5 Hz, 1H, H-8), 4.39 (t, *J* = 7.5 Hz, 2H, H-1′), 2.36 (s, 3H, Ar---[CH~3~]{.ul}), 1.66 (quintuplet, *J* = 7.5 Hz, 2H, H-2′), 1.34 (m, 2H, H-3′), 0.93 (t, *J* = 7.5 Hz, 3H, H-4′); ^13^C NMR (DMSO-*d*~6~) *δ* (ppm): 174.9 (C-2), 159.7 (C-4), 137.5 (C-4b), 136.9 (C-6), 134.5 (C-7), 127.0 (C-5), 116.0 (C-8), 115.8 (C-4a), 45.9 (C-1′), 28.9 (C-2′), 20.9 (Ar---[CH~3~]{.ul}), 20.1 (C-3′), 14.2 (C-4′); ESI-MS (*m*/*z*): 247.3 \[M−H\]^−^ (negative mode) for molecular weight (MW) = 248.34.

2.3. General procedure for the Preparation of compounds **4**--**23** {#s0025}
---------------------------------------------------------------------

Potassium carbonate (1.2 mmol) was added portion-wise over a period of 5 min to a mixture of compounds **1**, **2** or **3** (1 mmol) in DMF (8 mL) at room temperature. The appropriate alkyl halide (1.5 mmol) was then added, and the reaction mixture was stirred at 90 °C for 18 h. The mixture was poured into ice/water, and the precipitate was filtered off, washed with water, and dried ([@b0055]).

### 2.3.1. 3-Butyl-2-(ethylthio)-6-methylquinazolin-4(3*H*)-one (**4**) {#s0030}

White amorphous powder; yield: 77%; mp: 89--90 °C; ^1^H NMR (DMSO-*d*~6~) *δ* (ppm): 7.86 (br s, 1H, H-5), 7.59 (br d, *J* = 8 Hz, 1H, H-7), 7.44 (d, *J* = 8.5 Hz, 1H, H-8), 4.02 (t, *J* = 7.5 Hz, 2H, H-1″), 3.26 (q, *J* = 7.5 Hz, 2H, H-1′), 2.42 (s, 3H, Ar---CH~3~), 1.65 (quintuplet, *J* = 7.5 Hz, 2H, H-2″), 1.37 (m, 5H, H-2′, H-3″), 0.93 (t, *J* = 7.5 Hz, 3H, H-4″); ^13^C NMR (DMSO-*d*~6~) *δ* (ppm): 160.9 (C-4), 155.8 (C-2), 145.5 (C-4b), 136.3 (C-7), 135.8 (C-6), 126.2 (C-5), 126.1 (C-8), 118.9 (C-4a), 44.1 (C-1″), 30.1 (C-2″), 26.3 (C-1′), 21.2 (Ar---CH~3~), 20.1 (C-3″), 14.4 (C-2′), 14.1 (C-4″); ESI-MS (*m*/*z*): 275.4 \[M−H\]^−^ (negative mode) for MW = 276.40.

### 2.3.2. 2-(Allylthio)-3-butyl-6-methylquinazolin-4(3*H*)-one (**5**) {#s0035}

Pale yellow amorphous powder; yield: 80%; mp: 67--68 °C; ^1^H NMR (DMSO-*d*~6~) *δ* (ppm): 7.86 (br s, 1H, H-5), 7.59 (br d, *J* = 8 Hz, 1H, H-7), 7.45 (d, *J* = 8.5 Hz, 1H, H-8), 6.00 (m, 1H, H-2′), 5.41 (br d, *J* = 17 Hz, 1H, H-3a′), 5.18 (br d, *J* = 10 Hz, 1H, H-3b′), 4.02 (t, *J* = 7.5 Hz, 2H, H-1″), 3.96 (d, *J* = 7 Hz, 2H, H-1′), 2.42 (s, 3H, Ar---CH~3~), 1.65 (quintuplet, *J* = 7.5 Hz, 2H, H-2″), 1.35 (m, 2H, H-3″), 0.93 (t, *J* = 7.5 Hz, 3H, H-4″); ^13^C NMR (DMSO-*d*~6~) *δ* (ppm): 160.9 (C-4), 155.1 (C-2), 145.4 (C-4b), 136.3 (C-7), 135.9 (C-6), 133.4 (C-2′), 126.3 (C-5), 126.1 (C-8), 119.5 (C-3′), 119.0 (C-4a), 44.1 (C-1″), 34.5 (C-1′), 30.1 (C-2″), 21.2 (Ar---CH~3~), 20.1 (C-3″), 14.0 (C-4″); ESI-MS (*m*/*z*): 287.1 \[M−H\]^−^ (negative mode) for MW = 288.41.

### 2.3.3. 3-Butyl-6-methyl-2-(2-methylbenzylthio)-quinazolin-4(3*H*)-one (**6**) {#s0040}

White amorphous powder; yield: 77%; mp: 101--102 °C; ^1^H NMR (DMSO-*d*~6~) *δ* (ppm): 7.87 (br s, 1H, H-5), 7.63 (br d, *J* = 8 Hz, 1H, H-7), 7.53 (d, *J* = 8.5 Hz, 1H, H-8), 7.49 (d, *J* = 8.5 Hz, 1H, H-3′), 7.20--7.10 (m, 3H, H-4′,5′,6′), 4.56 (s, 2H, H-7′), 4.00 (t, *J* = 7.5 Hz, 2H, H-1″), 2.43 (s, 3H, ---CH~2~---Ar---CH~3~), 2.42 (s, 3H, Ar---CH~3~), 1.62 (quintuplet, *J* = 7.5 Hz, 2H, H-2″), 1.33 (m, 2H, H-3″), 0.90 (t, *J* = 7.5 Hz, 3H, H-4″); ^13^C NMR (DMSO-*d*~6~) *δ* (ppm): 160.9 (C-4), 155.5 (C-2), 145.4 (C-4b), 137.4 (C-1′), 136.4 (C-7), 136.0 (C-6), 134.4 (C-2′), 130.9 (C-3′), 130.8 (C-4′), 128.3 (C-6′), 126.5 (C-5′), 126.3 (C-5), 126.2 (C-8), 119.1 (C-4a), 44.2 (C-1″), 34.5 (C-7′), 30.1 (C-2″), 21.2 (Ar---CH~3~), 20.0 (C-3″), 19.4 (---CH~2~---Ar---CH~3~), 14.0 (C-4″); ESI-MS (*m*/*z*): 351.1 \[M−H\]^−^ (negative mode) for MW = 352.50.

### 2.3.4. 3-Butyl-6-methyl-2-(3-methylbenzylthio)-quinazolin-4(3*H*)-one (**7**) {#s0045}

Pale yellow amorphous powder; yield: 80%; mp: 84--85 °C; ^1^H NMR (DMSO-*d*~6~) *δ* (ppm): 7.87 (br s, 1H, H-5), 7.62 (br d, *J* = 8 Hz, 1H, H-7), 7.52 (d, *J* = 8.5 Hz, 1H, H-8), 7.32 (br s, 1H, H-2′), 7.30 (br d, *J* = 8 Hz, 1H, H-4′), 7.21 (t-like, *J* = 8 Hz, 1H, H-5′), 7.07 (br d, *J* = 8 Hz, 1H, H-6′), 4.50 (s, 2H, H-7′), 4.00 (t, *J* = 7.5 Hz, 2H, H-1″), 2.42 (s, 3H, Ar---CH~3~), 2.28 (s, 3H, ---CH~2~---Ar---CH~3~), 1.61 (quintuplet, *J* = 7.5 Hz, 2H, H-2″), 1.34 (m, 2H, H-3″), 0.92 (t, *J* = 7.5 Hz, 3H, H-4″); ^13^C NMR (DMSO-*d*~6~) *δ* (ppm): 160.9 (C-4), 155.4 (C-2), 145.4 (C-4b), 138.0 (C-1′), 136.9 (C-3′), 136.4 (C-7), 136.0 (C-6), 130.5 (C-5′), 128.8 (C-4′), 128.5 (C-2′), 126.9 (C-6′), 126.2 (C-5), 126.1 (C-8), 119.0 (C-4a), 44.1 (C-1″), 36.0 (C-7′), 30.1 (C-2″), 21.4 (---CH~2~---Ar---CH~3~), 21.2 (Ar---CH~3~), 20.0 (C-3″), 14.0 (C-4″); ESI-MS (*m*/*z*): 351.1 \[M−H\]^−^ (negative mode) for MW = 352.50.

### 2.3.5. 3-Butyl-2-(4-chlorobenzylthio)-6-methyl-3*H*-quinazolin-4-one (**8**) {#s0050}

White amorphous powder; yield: 70%; mp: 110--111 °C; ^1^H NMR (DMSO-*d*~6~) *δ* (ppm): 7.86 (br s, 1H, H-5), 7.63 (br d, *J* = 8 Hz, 1H, H-7), 7.55 (d, *J* = 8 Hz, 2H, H-3′/5′), 7.53 (d, *J* = 8.5 Hz, 1H, H-8), 7.38 (d, *J* = 8 Hz, 2H, H-2′/6′), 4.54 (s, 2H, H-7′), 4.01 (t, *J* = 7.5 Hz, 2H, H-1″), 2.43 (s, 3H, Ar---CH~3~), 1.63 (quintuplet, *J* = 7.5 Hz, 2H, H-2″), 1.33 (m, 2H, H-3″), 0.91 (t, *J* = 7.5 Hz, 3H, H-4″); ^13^C NMR (DMSO-*d*~6~) *δ* (ppm): 160.9 (C-4), 155.1 (C-2), 145.3 (C-4b), 136.7 (C-4′), 136.4 (C-7), 136.1 (C-6), 132.4 (C-1′), 131.7 (C-3′/5′), 128.8 (C-2′/6′), 126.3 (C-5), 126.2 (C-8), 119.0 (C-4a), 44.2 (C-1″), 35.0 (C-7′), 30.1 (C-2″), 21.2 (Ar---CH~3~), 20.0 (C-3″), 14.0 (C-4″); ESI-MS (*m*/*z*): 371.0 \[M−H\]^−^ (negative mode) for MW = 372.91.

### 2.3.6. 3-butyl-6-methyl-2-(4-Nitrobenzylthio)quinazolin-4(3H)-one (**9**) {#s0055}

White amorphous powder; yield: 82%; mp: 146--147 °C; ^1^H NMR (DMSO-*d*~6~) *δ* (ppm): 8.18 (d, *J* = 8 Hz, 2H, H-3′/5′), 7.85 (br s, 1H, H-5), 7.82 (d, *J* = 8 Hz, 2H, H-2′/6′), 7.63 (br d, *J* = 8 Hz, 1H, H-7), 7.55 (d, *J* = 8.5 Hz, 1H, H-8), 4.67 (s, 2H, H-7′), 4.02 (t, *J* = 7.5 Hz, 2H, H-1″), 2.42 (s, 3H, Ar---CH~3~), 1.66 (quintuplet, *J* = 7.5 Hz, 2H, H-2″), 1.35 (m, 2H, H-3″), 0.92 (t, *J* = 7.5 Hz, 3H, H-4″); ^13^C NMR (DMSO-*d*~6~) *δ* (ppm): 160.9 (C-4), 155.2 (C-2), 147.1 (C-4′), 146.2 (C-1′), 145.2 (C-4b), 136.4 (C-7), 136.2 (C-6), 131.7 (C-2′/6′), 126.3 (C-5), 126.2 (C-8), 123.9 (C-3′/5′), 119.1 (C-4a), 44.2 (C-1″), 34.9 (C-7′), 30.1 (C-2″), 21.2 (Ar---CH~3~), 20.0 (C-3″), 14.0 (C-4″); ESI-MS (*m*/*z*): 382.1 \[M−H\]^−^ (negative mode) for MW = 383.47.

### 2.3.7. 2-\[(3-Butyl-3,4-dihydro-6-methyl-4-oxoquinazolin-2-ylthio)methyl\]benzo nitrile (**10**) {#s0060}

White amorphous powder; yield: 76%; mp: 128--129 °C; ^1^H NMR (DMSO-*d*~6~) *δ* (ppm): 7.85 (br s, 1H, H-5), 7.82 (br d, *J* = 8 Hz, 1H, H-6′), 7.67 (t-like, *J* = 8 Hz, 1H, H-5′), 7.62 (br d, *J* = 8 Hz, 1H, H-7), 7.60 (br d, *J* = 8 Hz, 1H, H-3′), 7.56 (d, *J* = 8.5 Hz, 1H, H-8), 7.46 (t-like, 1H, H-4′) 4.70 (s, 2H, H-7′), 4.01 (t, *J* = 7.5 Hz, 2H, H-1″), 2.41 (s, 3H, Ar---CH~3~), 1.64 (quintuplet, *J* = 7.5 Hz, 2H, H-2″), 1.35 (m, 2H, H-3″), 0.91 (t, *J* = 7.5 Hz, 3H, H-4″); ^13^C NMR (DMSO-*d*~6~) *δ* (ppm): 160.8 (C-4), 154.5 (C-2), 145.3 (C-4b), 141.4 (C-1′), 136.4 (C-7), 136.2 (C-6), 133.7 (C-5′), 133.4 (C-3′), 131.1 (C-6′), 128.7 (C-4′), 126.2 (C-5), 126.1 (C-8), 119.1 (C-4a), 118.2 (---CN), 112.8 (C-2′), 44.2 (C-1″), 34.1 (C-7′), 30.1 (C-2″), 21.2 (Ar---CH~3~), 20.0 (C-3″), 14.0 (C-4″); ESI-MS (*m*/*z*): 362.0 \[M−H\]^−^ (negative mode) for MW = 363.48.

### 2.3.8. 3-\[(3-Butyl-3,4-dihydro-6-methyl-4-oxoquinazolin-2-ylthio)methyl\]benzo nitrile (**11**) {#s0065}

White amorphous powder; yield: 71%; mp: 139--140 °C; ^1^H NMR (DMSO-*d*~6~) *δ* (ppm): 8.02 (br s, 1H, H-2′), 7.88 (br d, *J* = 8 Hz, 1H, H-6′), 7.86 (br s, 1H, H-5), 7.63 (br d, *J* = 8 Hz, 1H, H-7), 7.56 (d, *J* = 8.5 Hz, 1H, H-8), 7.54 (m, 2H, H-4′,5′), 4.58 (s, 2H, H-7′), 4.01 (t, *J* = 7.5 Hz, 2H, H-1″), 2.42 (s, 3H, Ar---CH~3~), 1.63 (quintuplet, *J* = 7.5 Hz, 2H, H-2″), 1.34 (m, 2H, H-3″), 0.91 (t, *J* = 7.5 Hz, 3H, H-4″); ^13^C NMR (DMSO-*d*~6~) *δ* (ppm): 160.9 (C-4), 154.9 (C-2), 145.2 (C-4b), 139.8 (C-1′), 136.5 (C-7), 136.2 (C-6), 134.8 (C-6′), 133.5 (C-2′), 131.5 (C-4′), 130.0 (C-5′), 126.2 (C-5), 126.1 (C-8), 119.1 (C-4a), 119.0 (---CN), 111.7 (C-3′), 44.2 (C-1″), 34.8 (C-7′), 30.1 (C-2″), 21.2 (Ar---CH~3~), 20.0 (C-3″), 14.0 (C-4″); ESI-MS (*m*/*z*): 362.0 \[M−H\]^−^ (negative mode) for MW = 363.48.

### 2.3.9. 4-\[(3-Butyl-3,4-dihydro-6-methyl-4-oxoquinazolin-2-ylthio)methyl\]benzo nitrile (**12**) {#s0070}

White amorphous powder; yield: 78%; mp: 124--125 °C; ^1^H NMR (DMSO-*d*~6~) *δ* (ppm): 7.85 (br s, 1H, H-5), 7.79 (d, *J* = 8 Hz, 2H, H-3′/5′), 7.73 (d, *J* = 8 Hz, 2H, H-2′/6′), 7.62 (br d, *J* = 8 Hz, 1H, H-7), 7.52 (d, *J* = 8.5 Hz, 1H, H-8), 4.61 (s, 2H, H-7′), 4.00 (t, *J* = 7.5 Hz, 2H, H-1″), 2.42 (s, 3H, Ar---CH~3~), 1.62 (quintuplet, *J* = 7.5 Hz, 2H, H-2″), 1.34 (m, 2H, H-3″), 0.91 (t, *J* = 7.5 Hz, 3H, H-4″); ^13^C NMR (DMSO-*d*~6~) *δ* (ppm): 160.9 (C-4), 154.9 (C-2), 145.2 (C-4b), 143.9 (C-1′), 136.4 (C-7), 136.2 (C-6), 132.7 (C-3′/5′), 130.8 (C-2′/6′), 126.2 (C-5), 126.1 (C-8), 119.2 (C-4a), 119.0 (---CN), 110.5 (C-4′), 44.2 (C-1″), 35.2 (C-7′), 30.1 (C-2″), 21.2 (Ar---CH~3~), 20.0 (C-3″), 14.0 (C-4″); ESI-MS (*m*/*z*): 362.0 \[M−H\]^−^ (negative mode) for MW = 363.48.

### 2.3.10. 3-Butyl-6-methyl-2-(3-methoxybenzylthio)-quinazolin-4(3*H*)-one (**13**) {#s0075}

White amorphous powder; yield: 80%; mp: 83--84 °C; ^1^H NMR (DMSO-*d*~6~) *δ* (ppm): 7.87 (br s, 1H, H-5), 7.61 (br d, *J* = 8 Hz, 1H, H-7), 7.53 (d, *J* = 8.5 Hz, 1H, H-8), 7.24 (t-like, *J* = 8 Hz, 1H, H-5′), 7.11 (br s, 1H, H-2′), 7.08 (br d, *J* = 8 Hz, 1H, H-4′), 6.83 (br d, *J* = 8 Hz, 1H, H-6′), 4.51 (s, 2H, H-7′), 4.01 (t, *J* = 7.5 Hz, 2H, H-1″), 3.73 (s, 3H, ---OCH~3~), 2.43 (s, 3H, Ar---CH~3~), 1.63 (quintuplet, *J* = 7.5 Hz, 2H, H-2″), 1.33 (m, 2H, H-3″), 0.90 (t, *J* = 7.5 Hz, 3H, H-4″); ^13^C NMR (DMSO-*d*~6~) *δ* (ppm): 160.9 (C-4), 159.7 (C-3′), 155.4 (C-2), 145.3 (C-4b), 138.8 (C-1′), 136.4 (C-7), 136.0 (C-6), 130.0 (C-5′), 126.2 (C-5), 126.1 (C-8), 122.0 (C-6′), 119.0 (C-4a), 115.4 (C-4′), 113.4 (C-2′), 55.5 (---OCH~3~), 44.1 (C-1″), 35.9 (C-7′), 30.1 (C-2″), 21.2 (Ar---CH~3~), 20.0 (C-3″), 14.0 (C-4″); ESI-MS (*m*/*z*): 367.3 \[M−H\]^−^ (negative mode) for MW = 368.50.

### 2.3.11. 2-\[(1*H*-benzo\[*d*\]imidazol-2-yl)methylthio\]-3-butyl-6-methylquinazolin-4(3*H*)-one (**14**) {#s0080}

Brown amorphous powder; yield: 45%; mp: 114--115 °C; ^1^H NMR (DMSO-*d*~6~) *δ* (ppm): 12.45 (br s, 1H, NH), 7.87 (br s, 1H, H-5), 7.61 (br d, *J* = 8 Hz, 1H, H-7), 7.56 (d, *J* = 8.5 Hz, 1H, H-8), 7.16 (m, 4H, H-4′, 5′, 6′, 7′-benzimidazole), 4.80 (s, 2H, ---CH~2~---), 4.06 (t, *J* = 7.5 Hz, 2H, H-1″), 2.42 (s, 3H, Ar---CH~3~), 1.68 (quintuplet, *J* = 7.5 Hz, 2H, H-2″), 1.36 (m, 2H, H-3″), 0.93 (t, *J* = 7.5 Hz, 3H, H-4″); ^13^C NMR (DMSO-*d*~6~) *δ* (ppm): 160.9 (C-4), 154.9 (C-2), 150.3 (C-2′), 145.3 (C-4b), 136.9 (C-3′a, 7′a), 136.4 (C-7), 136.2 (C-6), 127.0 (C-5′, 6′), 126.4 (C-5), 126.1 (C-8), 119.1 (C-4a), 116.0 (C-4′, 7′), 44.3 (C-1″), 30.1 (C-2″), 28.9 (---CH~2~---), 21.2 (Ar---CH~3~), 20.1 (C-3″), 14.0 (C-4″); ESI-MS (*m*/*z*): 377.0 \[M−H\]^−^ (negative mode) for MW = 378.49.

### 2.3.12. 3-butyl-6-methyl-2-(2-Morpholinoethylthio)quinazolin-4(3H)-one (**15**) {#s0085}

Pale brown amorphous powder; yield: 60%. mp: 201--202 °C; ^1^H NMR (DMSO-*d*~6~) *δ* (ppm): 7.86 (br s, 1H, H-5), 7.60 (br d, *J* = 8 Hz, 1H, H-7), 7.56 (d, *J* = 8.5 Hz, 1H, H-8), 4.04 (t, *J* = 7.5 Hz, 2H, H-1″), 3.56 (t, *J* = 4.0 Hz, 4H, H-3′/5′), 3.40 (t, *J* = 7.5 Hz, 2H, CH~2~-7′), 2.67 (t, *J* = 7.5 Hz, 2H, CH~2~-8′), 2.47 (t, *J* = 4.0 Hz, 4H, H-2′/6′), 2.42 (s, 3H, Ar---CH~3~), 1.67 (quintuplet, *J* = 7.5 Hz, 2H, H-2″), 1.37 (m, 2H, H-3″), 0.93 (t, *J* = 7.5 Hz, 3H, H-4″); ^13^C NMR (DMSO-*d*~6~) *δ* (ppm): 159.7 (C-4), 155.9 (C-2), 145.4 (C-4b), 136.9 (C-7), 136.4 (C-6), 126.2 (C-5), 126.1 (C-8), 118.9 (C-4a), 66.7 (C-3′/5′), 57.4 (CH~2~-7′), 53.5 (C-2′/6′), 44.1 (C-1″), 30.1 (C-2″), 29.0 (CH~2~-8′), 21.2 (Ar---CH~3~), 20.1 (C-3″), 14.2 (C-4″); ESI-MS (*m*/*z*): 360.2 \[M−H\]^−^ (negative mode) for MW = 361.50.

### 2.3.13. 2-\[3-(3-Butyl-3,4-dihydro-6-methyl-4-oxoquinazolin-2-ylthio)propyl\]isoindo line-1,3-dione (**16**) {#s0090}

White amorphous powder; yield: 80%; mp: 105--106 °C; ^1^H NMR (DMSO-*d*~6~) *δ* (ppm): 7.87 (m, 4H, H-5′/6′, 4′/7′), 7.81 (br s, 1H, H-5), 7.47 (br d, *J* = 8 Hz, 1H, H-7), 7.07 (d, *J* = 8.5 Hz, 1H, H-8), 3.97 (t, *J* = 7.5 Hz, 2H, H-1″), 3.74 (t, *J* = 7 Hz, 2H, CH~2~-7′), 3.28 (t, *J* = 7 Hz, 2H, CH~2~-9′), 2.39 (s, 3H, Ar---CH~3~), 2.07 (quintuplet, *J* = 7.2 Hz, 2H, CH~2~-8′), 1.62 (quintuplet, *J* = 7.5 Hz, 2H, H-2″), 1.32 (m, 2H, H-3″), 0.90 (t, *J* = 7.5 Hz, 3H, H-4″); ^13^C NMR (DMSO-*d*~6~) *δ* (ppm): 168.5 (C-1′/3′), 160.9 (C-4), 155.5 (C-2), 145.3 (C-4b), 136.2 (C-7), 135.9 (C-6), 134.9 (C-3a′/7a′), 132.2 (C-5′/6′), 126.1 (C-5), 126.0 (C-8), 123.5 (C-4′/7′), 118.9 (C-4a), 44.0 (C-1″), 37.1 (CH~2~-7′), 34.6 (CH~2~-9′), 30.0 (C-2″), 28.3 (CH~2~-8′), 21.2 (Ar---CH~3~), 20.0 (C-3″), 14.0 (C-4″); ESI-MS (*m*/*z*): 434.4 \[M−H\]^−^ (negative mode) for MW = 435.54.

### 2.3.14. 4-\[(3-Benzyl-3,4-dihydro-6-methyl-4-oxoquinazolin-2-ylthio)methyl\]benzonitrile (**17**) {#s0095}

White amorphous powder; yield: 80%; mp: 174--175 °C (DMF); ^1^H NMR (500 MHz, DMSO-*d*~6~) *δ* (ppm): 7.91 (br s, 1H, H-5), 7.76 (d, *J* = 8 Hz, H-3′/5′), 7.68 (m, 3H, H-7, 2′/6′), 7.57 (d, *J* = 8 Hz, 1H, H-8), 7.32 (t-like, *J* = 7.5 Hz, 2H, H-3″/5″), 7.26 (br d, *J* = 7.5 Hz, 1H, H-4″), 7.19 (br d, *J* = 7.5 Hz, 2H, H-2″/6″), 5.30 (s, 2H, H-7″), 4.57 (s, 2H, H-7′), 2.44 (s, 3H, Ar---CH~3~); ^13^C NMR (125 MHz, DMSO-*d*~6~) *δ* (ppm): 161.3 (C-4), 155.3 (C-2), 145.3 (C-4b), 143.9 (C-1′), 136.7 (C-6), 136.5 (C-1″), 136.1 (C-7), 132.7 (C-3′/5′), 130.6 (C-2′/6′), 129.0 (C-3″/5″), 127.9 (C-4″), 127.1 (C-2″/6″), 126.4 (C-5), 126.3 (C-8), 119.2 (C-4a), 118.9 (---CN), 110.4 (C-4′), 47.2 (C-7″), 35.4 (C-7′), 21.2 (Ar---CH~3~); ESI-MS (*m*/*z*): 396.12 \[M−H\]^−^ (negative mode) for MW = 397.50.

### 2.3.15. 3-Benzyl-6-methyl-2-(3-methylbenzylthio)-quinazolin-4(3*H*)-one (**18**) {#s0100}

White amorphous powder; yield: 70%; mp: 130--131 °C (DMF); ^1^H NMR (500 MHz, DMSO-*d*~6~) *δ* (ppm): 7.92 (d, *J* = 1.5 Hz, 1H, H-5), 7.66 (dd, *J* = 8, 1.5 Hz, 1H, H-7), 7.57 (d, *J* = 8 Hz, 1H, H-8), 7.30--7.15 (m, 8H, H-2′, 4′, 5′, 3″/5″, 4″, 2″/6″), 7.06 (br d, *J* = 7.5 Hz, 1H, H-6′), 5.30 (s, 2H, H-7″), 4.47 (s, 2H, H-7′), 2.45 (s, 3H, Ar---CH~3~), 2.26 (s, 3H, ---CH~2~---Ar---CH~3~); ^13^C NMR (125 MHz, DMSO-*d*~6~) *δ* (ppm): 161.4 (C-4), 155.9 (C-2), 145.4 (C-4b), 138.0 (C-1′), 136.8 (C-3′), 136.7 (C-6), 136.3 (C-1″), 136.2 (C-7), 130.4 (C-5′), 129.0 (C-4′), 128.9 (C-3″/5″), 128.5 (C-2′), 127.8 (C-2″/6″), 127.1 (C-6′), 126.9 (C-4″), 126.4 (C-5), 126.3 (C-8), 119.0 (C-4a), 47.1 (C-7″), 36.1 (C-7′), 21.4 (---CH~2~---Ar---CH~3~), 21.2 (Ar---CH~3~); ESI-MS (*m*/*z*): 385.15 \[M−H\]^−^ (negative mode) for MW = 386.51.

### 2.3.16. 3-Benzyl-6-methyl-2-(4-nitrobenzylthio)-quinazolin-4(3*H*)-one (**19**) {#s0105}

Yellow amorphous powder; yield: 72%; mp: 165--166 °C (DMF); ^1^H NMR (500 MHz, DMSO-*d*~6~) *δ* (ppm): 8.15 (d, *J* = 7.5 Hz, 2H, H-3′/5′), 7.94 (d, *J* = 7.5 Hz, 2H, H-2′/6′), 7.90 (br s, 1H, H-5), 7.67 (br d, *J* = 8 Hz, 1H, H-7), 7.59 (d, *J* = 8 Hz, 1H, H-8), 7.30 (t-like, *J* = 7.5 Hz, 2H, H-3″/5″), 7.21 (br d, *J* = 7.5 Hz, 1H, H-4″), 7.13 (br d, *J* = 7.5 Hz, 2H, H-2″/6″), 5.30 (s, 2H, H-7″), 4.62 (s, 2H, H-7′), 2.44 (s, 3H, Ar---CH~3~); ^13^C NMR (125 MHz, DMSO-*d*~6~) *δ* (ppm): 161.1 (C-4), 155.5 (C-2), 147.1 (C-4′), 146.0 (C-4b), 145.1 (C-1′), 136.7 (C-6), 136.6 (C-1″), 136.0 (C-7), 131.0 (C-2′/6′), 129.1 (C-3″/5″), 127.9 (C-4″), 127.4 (C-2″/6″), 127.0 (C-5), 126.4 (C-8), 123.8 (C-3′/5′), 119.2 (C-4a), 47.2 (C-7″), 35.1 (C-7′), 20.7 (Ar---CH~3~); ESI-MS (*m*/*z*): 416.1 \[M−H\]^−^ (negative mode) for MW = 417.48.

### 2.3.17. (3-Benzyl-6-methyl-2-(7-nitrobenzo\[*d*\]\[1,2,3\]oxadiazol-4-yl)thio)quinazolin-4(3*H*)-one (**20**) {#s0110}

Pale brown amorphous powder; yield: 54%; mp: 147--148 °C (DMF); ^1^H NMR (500 MHz, DMSO-*d*~6~) *δ* (ppm): 8.08 (d, *J* = 8 Hz, H-5′), 7.84 (br d, *J* = 8 Hz, 1H, H-5), 7.58 (br d, *J* = 8 Hz, 1H, H-7), 7.50--7.12 (m, 7H, H-6′, 3″/5″, 4″, 2″/6″, 8), 5.54 (s, 2H, H-7″), 2.44 (s, 3H, Ar---CH~3~); ^13^C NMR (125 MHz, DMSO-*d*~6~) *δ* (ppm): 161.8 (C-4), 159.0 (C-2), 145.0 (C-7′), 143.9 (C-4b), 139.1 (C-4′), 136.8 (C-6), 136.1 (C-1″), 136.1 (C-7), 131.1 (C-3a′), 130.8 (C- 5′), 129.0 (C-3″/5″), 127.8 (C-4″), 127.1 (C-2″/6″), 126.3 (C-5), 126.1 (C-8), 124.2 (C-7a′), 123.5 (C-6′), 118.9 (C-4a), 47.1 (C-7″), 21.1 (Ar---CH~3~); ESI-MS (*m*/*z*): 444.1 \[M−H\]^−^ (negative mode) for MW = 445.45.

### 2.3.18. 2-\[3-((3-Benzyl-6-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)thio)propyl\]isoin doline-1,3-dione (**21**) {#s0115}

White amorphous powder; yield: 78%; mp: 152--153 °C (DMF); ^1^H NMR (500 MHz, DMSO-*d*~6~) *δ* (ppm): 7.84 (m, 5H, H-5′/6′, 4′/7′, 5), 7.54 (dd, *J* = 8, 2 Hz, 1H, H-7), 7.32 (t-like, *J* = 7.5 Hz, 2H, H-3″/5″), 7.26 (br d, *J* = 7.5 Hz, 1H, H-4″), 7.20 (br d, *J* = 7.5 Hz, 2H, H-2″/6″), 7.12 (d, *J* = 8 Hz, 1H, H-8), 5.28 (s, 2H, H-7″), 3.71 (t, *J* = 7 Hz, 2H, CH~2~-7′), 3.24 (t, *J* = 7 Hz, 2H, CH~2~-9′), 2.42 (s, 3H, Ar---CH~3~), 2.03 (quintuplet, *J* = 70 Hz, 2H, CH~2~-8′); ^13^C NMR (125 MHz, DMSO-*d*~6~) *δ* (ppm): 168.5 (C-1′/3′), 161.3 (C-4), 155.6 (C-2), 145.4 (C-4b), 136.5 (C-6), 136.2 (C-1″), 136.1 (C-7), 134.9 (C-5′/6′), 132.2 (C-3a′/7a′), 129.0 (C-3″/5″), 127.8 (C-4″), 127.1 (C-2″/6″), 126.3 (C-5), 126.1 (C-8), 123.5 (C-4′/7′), 118.9 (C-4a), 47.1 (C-7″), 37.0 (CH~2~-7′), 29.3 (CH~2~-9′), 28.3 (CH~2~-8′), 21.2 (Ar---CH~3~); ESI-MS (*m*/*z*): 468.01 \[M−H\]^−^ (negative mode) for MW = 469.56.

### 2.3.19. 2-\[3-((3-Benzyl-8-methoxy-4-oxo-3,4-dihydroquinazolin-2-yl)thio)propyl\] isoindoline-1,3-dione (**22**) {#s0120}

Pale brown amorphous powder; yield: 85%; mp: 145--1146 °C (DMF); ^1^H NMR (500 MHz, DMSO-*d*~6~) *δ* (ppm): 7.82 (m, 4H, H-5′/6′, 4′/7′), 7.64 (br d, *J* = 8 Hz, 1H, H-5), 7.38 (t-like, *J* = 8 Hz, 1H, H-6), 7.34 (br d, *J* = 8 Hz, 1H, H-7), 7.31 (t-like, *J* = 7.5 Hz, 2H, H-3″/5″), 7.27 (br d, *J* = 7.5 Hz, 1H, H-4″), 7.23 (br d, *J* = 7.5 Hz, 2H, H-2″/6″), 5.30 (s, 2H, H-7″), 3.79 (s, 3H, ---OCH~3~), 3.72 (t, *J* = 7 Hz, 2H, CH~2~-7′), 3.31 (t, *J* = 7 Hz, 2H, CH~2~-9′), 2.08 (quintuplet, *J* = 70 Hz, 2H, CH~2~-8′); ^13^C NMR (125 MHz, DMSO-*d*~6~) *δ* (ppm): 168.4 (C-1′/3′), 161.4 (C-4), 155.7 (C-2), 153.9 (C-8), 138.0 (C-4b), 136.1 (C-1″), 134.8 (C-5′/6′), 132.1 (C-3a′/7a′), 129.0 (C-3″/5″), 127.8 (C-6), 127.1 (C-2″/6″), 126.7 (C-4″), 123.4 (C-4′/7′), 120.1 (C-4a), 117.9 (C-7), 116.1 (C-5), 56.7 (---OCH~3~), 47.3 (C-7″), 37.0 (CH~2~-7′), 29.6 (CH~2~-9′), 28.1 (CH~2~-8′); ESI-MS (*m*/*z*): 484.1 \[M−H\]^−^ (negative mode) for MW = 485.56.

### 2.3.20. 3-Benzyl-8-methoxy-2-((2-morpholinoethyl)thio)quinazolin-4(3*H*)-one (**23**) {#s0125}

Pale yellow amorphous powder; yield: 65%; mp: 129--130 °C (DMF); ^1^H NMR (500 MHz, DMSO-*d*~6~) *δ* (ppm): 7.52 (br d, *J* = 8 Hz, 1H, H-5), 7.41--7.37 (m, 2H, H-6, 7), 7.31 (t-like, *J* = 7.5 Hz, 2H, H-3″/5″), 7.26 (br d, *J* = 7.5 Hz, 1H, H-4″), 7.22 (br d, *J* = 7.5 Hz, 2H, H-2″/6″), 5.32 (s, 2H, H-7″), 3.89 (s, 3H, ---OCH~3~), 3.53 (t, *J* = 4.0 Hz, 4H, H-3′/5′), 3.40 (t, *J* = 7 Hz, 2H, CH~2~-7′), 2.64 (t, *J* = 7 Hz, 2H, CH~2~-8′), 2.47 (t, *J* = 4.0 Hz, 4H, H-2′/6′); ^13^C NMR (125 MHz, DMSO-*d*~6~) *δ* (ppm): 161.4 (C-4), 156.0 (C-2), 153.9 (C-8), 138.1 (C-4b), 136.2 (C-1″), 129.0 (C-3″/5″), 127.8 (C-6), 127.1 (C-2″/6″), 126.7 (C-4″), 120.1 (C-4a), 117.9 (C-7), 116.5 (C-5), 66.7 (C-3′/5′), 57.5 (CH~2~-7′), 56.6 (C---OCH~3~), 53.5 (C-2′/6′), 47.3 (C-7″), 29.0 (CH~2~-8′); ESI-MS (*m*/*z*): 410.1 \[M−H\]^−^ (negative mode) for MW = 411.52.

2.4. Preparation of 2-hydrazinyl-6-methyl-3*H*-quinazolin-4-ones (**24** and **25**) {#s0130}
------------------------------------------------------------------------------------

Compound **1** or **3** (1 mmol) was boiled with hydrazine hydrate (5 mmol) in ethanol (10 mL) for 7 h under reflux. The mixture was cooled, and the precipitate was filtered, washed with water and dried.

### 2.4.1. 3-Butyl-2-hydrazinyl-6-methyl-3*H*-quinazolin-4-one (**24**) {#s0135}

White amorphous powder; yield: 76%; mp: 177--178 °C; ^1^H NMR (DMSO-*d*~6~) *δ* (ppm): 9.44 (s, 1H, ---NH---), 8.08 (d, *J* = 8.5 Hz, 1H, H-8), 7.97 (br s, 1H, H-5), 7.73 (br d, *J* = 8 Hz, 1H, H-7), 6.21 (br s, 2H, ---NH~2~), 4.17 (t, *J* = 7.5 Hz, 2H, H-1′), 2.45 (s, 3H, Ar---CH~3~), 1.74 (quintuplet, *J* = 7.5 Hz, 2H, H-2′), 1.37 (m, 2H, H-3′), 0.92 (t, *J* = 7.5 Hz, 3H, H-4′); ^13^C NMR (DMSO-*d*~6~) *δ* (ppm): 158.6 (C-4), 147.8 (C-2), 137.0 (C-4b), 136.2 (C-7), 130.9 (C-6), 128.9 (C-5), 116.7 (C-4a), 116.2 (C-8), 42.8 (C-1′), 29.3 (C-2′), 21.0 (Ar---CH~3~), 20.1 (C-3′), 14.1 (C-4′); ESI-MS (*m*/*z*): 245.1 \[M−H\]^−^ (negative mode) for MW = 246.31.

### 2.4.2. 3-Benzyl-2-hydrazinyl-6-methylquinazolin-4(3*H*)-one (**25**) {#s0140}

White amorphous powder; yield: 62%; mp: 200--201 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~) *δ* (ppm): 8.28 (s, 1H, ---NH---), 7.77 (br s, 1H, H-5), 7.47 (br d, *J* = 8 Hz, 1H, H-7), 7.35--7.22 (m, 6H, H-2′-6′, 8), 5.25 (s, 2H, H-7′), 4.41 (br s, 2H, ---NH~2~), 2.45 (s, 3H, Ar---CH~3~); ^13^C NMR (125 MHz, DMSO-*d*~6~) *δ* (ppm): 162.0 (C-4), 152.2 (C-2), 136.8 (C-4b), 136.6 (C-6), 136.4 (C-1′), 136.2 (C-7), 130.8 (C-6), 128.9 (C-5), 128.8 (C-3′/5′), 127.2 (C-2′/6′), 126.5 (C-4′), 116.6 (C-4a), 116.1 (C-8), 43.9 (C-7′), 20.9 (Ar---CH~3~); ESI-MS (*m*/*z*): 279.1 \[M−H\]^−^ (negative mode) for MW = 280.33.

2.5. Preparation of 4-butyl-7-methyl-\[1,2,4\]triazolo\[4,3-*a*\]quinazolin-5(4*H*)-one (**26**) {#s0145}
------------------------------------------------------------------------------------------------

A mixture of compound **24** (1 mmol) and dimethyl-*N*-cyanoimidodithiocarbonate (1 mmol) in DMF (8 mL) was refluxed in the presence of Et~3~N for 4 h. The mixture was then poured into ice water, and the resulting solid was separated, washed with water, and dried. Alternatively, compound **24** (1 mmol) was refluxed with formic acid (5 mL) for 7 h. The mixture was cooled, and the resulting solid was separated and dried. White amorphous powder; yield: 41%; mp: 183--184 °C; ^1^H NMR (500 MHz, DMSO-*d*~6~) *δ* (ppm): 9.46 (s, 1H, ---N---C*[H]{.ul}*000000000000 000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000 000000000000N---), 8.07 (d, *J* = 8.5 Hz, 1H, H-8), 8.00 (br s, 1H, H-5), 7.76 (br d, *J* = 8 Hz, 1H, H-7), 4.19 (t, *J* = 7.5 Hz, 2H, H-1′), 2.46 (s, 3H, Ar---CH~3~), 1.74 (quintuplet, *J* = 7.5 Hz, 2H, H-2′), 1.38 (m, 2H, H-3′), 0.95 (t, *J* = 7.5 Hz, 3H, H-4′); ^13^C NMR (125 MHz, DMSO-*d*~6~) *δ* (ppm): 158.7 (C-4), 147.8 (C-2), 137.0 (---N---C*H*N---), 136.2 (C-6), 136.3 (C-4b), 130.9 (C-7), 128.9 (C-5), 116.7 (C-4a), 116.3 (C-8), 42.8 (C-1′), 29.3 (C-2′), 21.0 (Ar---CH~3~), 20.0 (C-3′), 14.1 (C-4′); ESI-MS (*m*/*z*): 255.1 \[M−H\]^−^ (negative mode) for MW = 256.31.

2.6. Cell culture {#s0150}
-----------------

The human breast cancer (MDA-MB231) and cervical cancer (HeLa) cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin (10,000 U) and streptomycin (10 mg) in 74 cm^2^ flasks and incubated until 80% confluence was reached in a humidified environment of 5% CO~2~/95% air at 37 °C. The cells were seeded and maintained in triplicate in a 96-well tissue culture plate at 5 × 10^4^ cells/well in 150 μL of the growth medium for experimental purposes and allowed to attach for 24 h before treatment. The cells were then treated with the synthesized compounds (**1**--**26**) and gefitinib (standard) at 0, 1, 5, 10, 25, and 50 μM and incubated for 24 h. DMSO was used as a negative control, as all compounds were dissolved in 50% DMSO. The DMSO concentration in each well was maintained at less than 0.1%. After 24 h, the growth medium was replaced with 100 μl of serum-free medium containing MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), 5 mg/mL) and incubated for 4 h at 5% CO~2~/95% air and 37 °C. MTT, which is a yellow, water-soluble tetrazolium salt, is cleaved by mitochondrial dehydrogenases leading to the formation of the purple, water-insoluble formazan, which cannot pass through the cell membrane and therefore accumulates in healthy cells ([@b0090]). The old medium was then discarded, and the formazan was dissolved by adding 100 μl of isopropanol. The absorbance of the 96-well plate was measured at 570 nm using a Mithras^2^ LB 943 monochromator multimode reader (Berthold Technologies) against the reagent blank.

3. Results and discussion {#s0155}
=========================

3.1. Chemistry of the synthesized compounds {#s0160}
-------------------------------------------

The 2-thioxo-2,3-dihydroquinazolin-4-ones **1** and **2**, were synthesized as previously described in literature ([@b0015], [@b0005]), and their structures were confirmed via X-ray crystallography ([Fig.2](#f0010){ref-type="fig"}a and b) ([@b0025], [@b0030]). In the present study, 3-butyl-6-methyl-2-thioxo-2,3-dihydroquinazolin-4-one (**3)** was obtained successfully at a high yield of 87% by treating 2-amino-5-methylbenzoic acid with butyl isothiocyanate in the presence of Et~3~N under reflux conditions ([Scheme 1](#f0015){ref-type="fig"}). The structure of compound **3** was characterized via NMR spectroscopy and unambiguously confirmed via X-ray crystallography ([Fig.2](#f0010){ref-type="fig"}c).Fig. 2Three-dimensional structures of compounds **1**--**3.**Scheme 1The synthetic routes for compounds **1**--**26.**

In the presence of potassium carbonate, the reaction of compounds **1**--**3** with different alkyl (heteroalkyl) halides in boiling DMF smoothly afforded the expected thioethers (**4**--**23**) in 45--85% yields ([Scheme 1](#f0015){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}). Hydrazinolysis of compounds **1** and **3** in boiling ethanol led to the formation of the corresponding 2-hydrazinyl-6-methyl-quinazolin-4-ones (**24** and **25)** with a good yield of 76% and 62%, respectively. The reaction of compound **3** with dimethyl-*N*-cyanoimidodithiocarbonate or formic acid under reflux furnished the tricyclic product (**26**) in good yield. The thioethers (**4**--**24**), hydrazino (**24** and **25**) and tricyclic (**26**) products were obtained as pure, colored amorphous powders and their structures were confirmed via NMR analysis. The presence of the basic 2-thioxoquinazoline unit in most compounds was confirmed through its three characteristic aromatic signals of the benzene moiety observed at *δ* (ppm): 7.8 (br s, H-5), 7.6 (br d, H-7), and 7.5 (d, H-8). In addition, a singlet of 3H was assigned at approximately 2.45 ppm for the 6-CH~3~ group, which was indicated in all the ^13^C NMR spectra at about 21.0 ppm. Moreover, the four intrinsic ^1^H-resonances of the *N*-butyl functional group were recorded at *δ* (ppm): 4.2 (t, H-1′), 1.7 (quintuplet, H-2′), 1.4 (m, H-3′), and 0.90 (t, H-4′), while their ^13^C signals were observed at 44.0, 30.0, 20.0, and 14.0 ppm, respectively. All the ^13^C NMR spectra of products **4**--**16** showed eight signals for the quinazoline moiety including the two key signals at 161 and 155 ppm, assignable to the C-4 carbonyl group and quaternary C-2 atom, respectively. The presence of the 2-thioxo functional group in compound **3** was confirmed by its unique carbon signal at 174.9 ppm. In the ^1^H NMR spectrum of compound **24**, the hydrazinyl group was assigned to two broad singlets at 9.44 and 6.21 ppm that are ascribable to the ---NH and ---NH~2~ protons, respectively. The formation of the *S*-benzyl derivatives (**6**--**13**) was also confirmed based on the observation of the ---*CH*~2~---Ar signal at 4.5--4.7 and 34--36 ppm in the ^1^H and ^13^C NMR spectra, respectively. Similarly, the characteristic NMR resonances of the ethyl, allyl, benzo\[*d*\]imidazol-2-yl, morpholinoethyl, and (phthalimido-2-yl)propyl) moieties were proof for the successful preparation of their derivatives (**4**, **5**, and **14**--**16**). The products **17**--**21** and **25** showed the characteristic NMR resonances of the *N*-benzyl moiety, which comprised of ---CH~2~--- as a singlet at 5.3 ppm in ^1^H NMR and at about 47.0 ppm in the ^13^C NMR spectra. They also showed three characteristic resonances of the H-5, H-7, and H-8 protons together with the typical singlet of the Ar-methyl group at 2.45 ppm and its ^13^C signal at 21.0 ppm. In the case of compounds **22** and **23**, the methoxylated C-8 appeared at 154.0 ppm, and the methoxy-CH~3~ was assigned at 3.8 ppm along with its ^13^C signal at 57.0 ppm. Moreover, the quinazoline moiety of compounds **17**--**23** was characterized by its characteristic ^13^C resonances, including the most downfield signals at 161.0 and 155.0 ppm that are ascribable to carbonyl C-4 and C-2, except in the case of compound **20,** in which C-2 was assigned at 159.0 ppm owing to the *S*-aryl group. In the case of compound **26**, the presence of the triazole ring was confirmed based on the appearance of its methine---H as a singlet at 9.46 ppm and its ^13^C signal at 137.0 ppm. Finally, it is worth mentioning to refer that the structure elucidation and the confirmation of all structures was achieved through a comparison study with the corresponding NMR data of related structure compounds ([@b0035], [@b0045], [@b0055]).Table 1Synthesized quinazoline derivatives (**1**--**26).**CompoundsRR1R2**1**MethylBenzyl--**2**MethoxyBenzyl--**3**MethylButyl--**4**MethylButylEthyl**5**MethylButylAllyl**6**MethylButyl2-Methyl-benzyl**7**MethylButyl3-Methyl-benzyl**8**MethylButyl4-Cl-benzyl**9**MethylButyl4-NO~2~-benzyl**10**MethylButyl2-CN-benzyl**11**MethylButyl3-CN-benzyl**12**MethylButyl4-CN-benzyl**13**MethylButyl3-Methoxy-benzyl**14**MethylButyl(1*H*-benzoimidazol-2-yl)methyl**15**MethylButylMorphilinoethyl**16**MethylButyl3-(Phthalimido-2-yl)propyl**17**MethylBenzyl4-CN-benzyl**18**MethylBenzyl3-Methyl-benzyl**19**MethylBenzyl4-NO~2~-benzyl**20**MethylBenzyl7-NO~2~-benzoxadiazole**21**MethylBenzyl3-(Phthalimido-2-yl)propyl**22**MethoxyBenzyl3-(Phthalimido-2-yl)propyl**23**MethoxyBenzylMorphilinoethyl**24**MethylButylHydrazine**25**MethylBenzylHydrazine**26**MethylButyl*--*

3.2. Antitumor activity of the synthesized compounds {#s0165}
----------------------------------------------------

Quinazolines have previously been demonstrated to be potent anticancer agents that are suitable for inhibiting EGFR-TKs ([@b0070], [@b0085], [@b0005], [@b0010], [@b0145], [@b0110]). Thus, the present study focused on evaluating the cytotoxicity of compounds **3**--**26** and comparing it with that of the parents (**1** and **2**). The *in vitro* cytotoxicity of the target compounds (**1**--**26)** was evaluated against the HeLa and MDA-MB231 carcinoma cell lines using gefitinib as a standard. The inhibition of cell proliferation was measured using the MTT assay ([@b0090]). Each cell line was incubated with six different concentrations (0--50 μM) of each compound, and the compound concentration versus survival fraction curves were created. The IC~50~ values of compounds **1**--**26** are shown in [Table 2](#t0010){ref-type="table"}. The cytotoxicity of all tested compounds (IC~50~ = 2.3--6.1 μM), with the exception of compound **11** (IC~50~ = 95.97 μM), against the MDA-MB231 cell line was higher than that of gefitinib (IC~50~ = 28.33 μM), with compound **15** showing good effectiveness (IC~50~ = 17.57 μM). Similarly, compounds **2**, **3, 8**, **10**, **17**, **18,** and **21**--**23** were more potent (IC~50~ = 1.85--3.9 μM) than gefitinib (IC~50~ = 4.3 μM) against the HeLa cell line. However, compounds **4**--**7**, **9**, **11, 15**, **16**, **19**, **20**, and **24**--**26** demonstrated good cytotoxicity against the HeLa cell line (IC~50~ = 4.1--6.3 μM), compounds **1** and **12**--**14** exhibited moderate activity (IC~50~ = 6.7--10.63 μM). The antitumor activity of the tested quinazoline derivatives (**1**--**26**) against the HeLa and MDA-MB231 cancer cell lines followed a distinctive pattern with compounds **21**--**23** exhibiting the most potent activity against both cell lines in this study. The anticancer activity of compounds **1**--**26** against HeLa and MDA-MB231 cells could be correlated with their structural modifications. An investigation of the diversity in the selectivity of compounds **1**--**26** for the two cell lines revealed that most of the tested compounds significantly inhibited both cell lines.Table 2Anticancer activity of the target compounds (**1**--**26**) (IC~50~, μM).CompoundsHeLa/IC~50~, μMMDA-MB231/IC~50~, μM**1**10.633.2**2**2.74.85**3**3.732.73**4**4.143.8**5**5.653.77**6**6.34.44**7**4.455**8**3.74.13**9**4.564.12**10**3.74.26**11**6.195.97**12**7.55.1**13**6.795.18**14**7.84.97**15**4.1117.57**16**5.756.19**17**3.92.93**18**3.044.96**19**5.63.23**20**4.143.5**21**1.852.33**22**2.52.56**23**2.62.81**24**5.392.74**25**4.775.6**26**5.035.74Gefitinib4.328.33

The parents **1**--**3** exhibited remarkable activity against HeLa and MDA-MB231 cells ([Table 2](#t0010){ref-type="table"}). However, compound **2** (IC~50~ = 2.7 μM) was more potent than compounds **1** and **3** (IC~50~ = 10.63 and 3.73 μM, respectively) against the HeLa cell line, indicating that the presence of an electro-donating group (OCH~3~) in compound **2** was essential for its activity. Compound **3** (IC~50~ = 2.73 μM) was more potent than compounds **1** and **2** (IC~50~ = 3.2 and 4.85 μM) against the MDA-MB231 carcinoma cell line. In this case, compound **3** showed higher activity against the MDA-MB231 cell line in relation to compound **2**, and against both cancer cell lines with respect to compound **1**. The increase in the cytotoxicity of compound **3** may be due to the presence of a highly lipophilic group (butyl) that enhances its activity.

The type of substituent incorporated at position 2 in compounds **1**--**3** was also found to be a major determinant of the cytotoxicity. Accordingly, the cytotoxicity increased in the order of **4, 5** \> **6**--**16** and **3**, **10** \> **4**--**9**, **11**--**16** against the MDA-MB231 and HeLa cell lines, respectively, in relation to compound **3** and gefitinib. The cytotoxicity profile was also affected by the variation and configuration of substituents on the *S*-benzyl ring, which was indicated by the increase in the anticancer activity of compounds **10**--**12** that contain the CN group, with compound **10** (IC~50~ = 3.7 and 4.26 μM) showing the highest activity. This indicates that the presence of the CN group in the *ortho* position enhanced the activity. Although the presence of a methoxy group in compound **13** did not enhance its cytotoxicity in comparison to compound **3,** it was beneficial for improving the efficacy of the parent molecule **2**. Incorporation of heteroalkyl groups into compound **3** afforded compounds **14**--**16** with slightly decreased cytotoxicity. Conversely, compounds **21**--**23** showed the highest activity against both carcinoma cell lines, and compounds **17** and **19** were more potent than compounds **9** and **12** against both cell lines. An explanation for this is that the presence of phthalimido, morpholino, NO~2~, and CN groups alongside the *N*-benzyl group might play a substantial role in the cytotoxicity and selectivity of these compounds. Hydrazinolysis of compounds **1** and **3** into compounds **24** and **25** influenced positively in the case of compounds **1** (IC~50~ = 4.77 μM) and **3** (IC~50~ = 2.74 μM) against the HeLa and MDA-MB231 cell line, respectively. The incorporation of a triazole ring in compound **26** caused a slight decrease in cytotoxicity. These variations in the anticancer activity profile of compounds **1**--**26** could also be correlated with the differences in the lipophilic substitution pattern of the quinazoline core.

4. Conclusion {#s0170}
=============

Our results indicated that all tested compounds (**1**--**26**) showed good activity against the HeLa and MDA-MB231 cancer cell lines. In particular, compounds **21**--**23**, which had the lowest IC~50~ values in relation to gefitinib, were identified as the most potent agents that probably act via the EGFR-TK pathway.

The obtained remarkable and significant cytotoxicity effects of compounds **21**--**23** (IC~50~ range of 1.85--2.81 μM) using aromatic and hetero substituent of the quinazoline core could be considered as useful template for future design and further derivatization or modification to obtain more compounds with potent cytotoxic effects.
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